Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

NEWS FEATURE

‘Business of science’ digest—January 2021

In our first monthly round up of the year we explore the big stories from 2020, including key biopharma deals, FDA approvals and IPOs, as well as the extraordinary impact of COVID-19 on science throughout an unusual 12 months.
Raveena obtained her bachelor's degree in biochemistry from the University of Leeds, UK. She has worked in the biopharma industry for more than 15 years, focusing on dealmaking, partnering and licensing throughout. In her first role, Raveena started as an editorial assistant, moving on to become content editor, specifically involved with conducting partner searches to identify both products/technologies and partners for pharmaceutical clients. She then worked for a biopharma reports publisher, editing and writing dealmaking-focused reports. In 2015 Raveena became the editor of Biopharma Dealmakers.

Search for this author in:

Pipette with transparent drop

Biopharma dealmaking in 2020

COVID-19 was the focus of multiple biopharma deals but the pandemic also affected the way companies did deals in general, from conducting due diligence, to becoming more adept at hosting meetings and negotiating virtually.

Nature Reviews Drug Discovery

2020 drug approvals

Despite disruptions caused by COVID-19, the US Food and Drug Administration Center for Drug Evaluation and Research (CDER) approved 53 novel therapeutics in 2020.

Nature Reviews Drug Discovery

2020 biotech IPOs shatter all the records

Public investor capital flooded into biotech companies entering the global public markets despite the COVID-19 pandemic, or in some cases because of it. The sector recorded just over 100 initial public offerings (IPOs), nearly double the number in 2019.

Nature Reviews Drug Discovery

COVID and 2020: An extraordinary year for science

The coronavirus pandemic shaped the year in research—from vaccines and treatments to campus shutdowns and virtual meetings.

Nature

2020 beyond COVID: the other science events that shaped the year

Mars missions, record-breaking wildfires and a room-temperature superconductor were among last year’s top non-COVID stories.

Nature

COVID vaccines: the world’s medical regulators need access to open data

The global race to produce COVID vaccines is a chance for regulators and drug companies to create a more harmonized approvals process.

Nature

These drugs might prevent severe COVID

Even with vaccines on the way, treatments are needed to prevent the disease from getting worse—and to be ready for COVID-25, COVID-37, and so on.

Scientific American

New year, new job?

How we landed jobs in industry

If you’re looking to switch sectors in 2021, here’s some advice from five cell biologists who left academia to pursue careers in biotechnology, biomedical and pharmaceutical companies.

Nature

A talent spotter’s tips

Biopharma industry recruiter Melisa Medrano is keen on candidates who are collaborative and can demonstrate strong technical skills. Here’s her advice on how to tailor your CV for industry employers.

Nature

Planning a postdoc before moving to industry?

If you think experience as a postdoctoral researcher will fast-track your career as a scientist working in industry, think again.

Nature Careers Podcast

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links